Delving into the Latest Updates on NT-503 with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms

Wet AMD encapsulated cell therapy, NT 503, NT-503-2

+ [2]

Target

VEGFR

Action

antagonists

Mechanism

VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)

Therapeutic Areas

Congenital DisordersEye DiseasesNervous System Diseases+ [2]

Active Indication-

Inactive Indication

Originator Organization

Neurotech Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Neurotech USA, Inc.Neurotech Pharmaceuticals, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 143413

Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate, randomized, masked phase during which eligible patients will be randomized to the NT-503-3 group or the control group.
Clinical Hypotheses:
* NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD
* NT-503-3 ECT has an acceptable safety profile

Start Date01 Sep 2014

Sponsor / Collaborator

Neurotech Pharmaceuticals, Inc.

PER-163-08

/ CompletedPhase 1

STUDY TO EVALUATE THE SAFETY AND VIABILITY OF THE IMPLEMENTATION OF NT-503 IN THE VITTURAL CAVITY FOR THE TREATMENT OF SUBFOVEAL COROID NEOVASCULARIZATION (NVC) SECONDARY TO AGE-ASSOCIATED MACULAR DEGENERATION (DMAE)

Start Date01 Jan 1900

Sponsor / Collaborator-

100 Clinical Results associated with NT-503

Login to view more data

100 Translational Medicine associated with NT-503

Login to view more data

100 Patents (Medical) associated with NT-503

Login to view more data

2

Literatures (Medical) associated with NT-503

13 Oct 2019·Expert opinion on pharmacotherapyQ3 · MEDICINE

Innovative therapies for neovascular age-related macular degeneration

Q3 · MEDICINE

Review

Author: Ciulla, Thomas A. ; Al-Khersan, Hasenin ; Dugel, Pravin U. ; Hussain, Rehan M.

Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial. Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, a single-chain antibody fragment, and Abicipar, a designed ankyrin repeat protein (DARPin). Other unique anti-VEGF agents in current trials include Conbercept - a fusion protein of the VEGF receptor domains, KSI-301 - an anti-VEGF antibody biopolymer conjugate, and OPT-302 - an inhibitor of VEGF-C/D. Strategies to activate the Tie-2 receptor, some in combination with VEGF inhibition, are of interest, with recent trials of Faricimab, ARP-1536, and nesvacumab. Topical anti-VEGF ± anti-PDGF agents, such as pazopanib, squalamine lactate, regorafenib, and LHA510 have shown limited efficacy and/or have not been advanced, although PAN-90806 continues to advance with promising initial results. Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.

03 Jul 2017·Expert opinion on emerging drugsQ2 · MEDICINE

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration

Q2 · MEDICINE

Review

Author: Hussain, Rehan M ; Ciulla, Thomas A.

INTRODUCTION:

Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability). X-82 is an oral anti-VEGF and anti-PDGF being tested in phase 2 studies. Topical anti-VEGF ± anti-PDGF drugs under study include pazopanib, PAN-90806, squalamine lactate, regorafinib, and LHA510. Sustained-release anti-VEGF delivery treatments, such as the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305 aim to reduce the burden of frequent injections. Gene therapies with new viral vectors hold the potential to induce sustained expression of anti-angiogenic proteins via the retina's cellular apparatus, and include AVA-101/201, ADVM-202/302, AAV2-sFLT01, RGX314, and Retinostat. Expert opinion: There are many emerging anti-VEGF treatments that aim to improve visual outcomes and reduce the treatment burden of nAMD.

100 Deals associated with NT-503

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Age Related Macular Degeneration	Phase 2	United States	Neurotech Pharmaceuticals, Inc.	01 Sep 2014
Age Related Macular Degeneration	Phase 2	Israel	Neurotech Pharmaceuticals, Inc.	01 Sep 2014
Glycogen Storage Disease Type II	Phase 2	United States	Neurotech Pharmaceuticals, Inc.	01 Sep 2014
Glycogen Storage Disease Type II	Phase 2	Israel	Neurotech Pharmaceuticals, Inc.	01 Sep 2014
Choroidal Neovascularization	Phase 2	United States	Neurotech Pharmaceuticals, Inc.	01 Sep 2014
Choroidal Neovascularization	Phase 2	Israel	Neurotech Pharmaceuticals, Inc.	01 Sep 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data